Retrieved results converge on the JAK2V617F mutation as the central oncogenic driver in PV, creating a dependency on sustained iron supply for pathological erythroid proliferation. PV is described across Protagonist Therapeutics patent filings as "a chronic, progressive trilineage clonal disorder signified by increased myeloid, erythroid, and megakaryocytic cell proliferation/accumulation," with diagnosis anchored to JAK2V617F or JAK2 exon 12 mutations, bone marrow trilineage hypercellularity, and subnormal serum erythropoietin levels.

The hepcidin/ferroportin/iron regulatory axis has emerged as a structurally distinct and mechanistically complementary approach to JAK inhibition. Protagonist Therapeutics' hepcidin mimetic filings and MabWell Therapeutics' TMPRSS6 antibody patents both frame JAK2/STAT5 overactivation as the rationale for targeting iron restriction — potentially enabling a phlebotomy-sparing strategy in PV. The WHO recognises myeloproliferative neoplasms as a significant haematological burden globally.

In ET, approximately 90% of patients harbour somatic mutations in JAK2V617F, CALR, or MPL, as noted in a Constellation Pharmaceuticals patent filing on bomedemstat. The BET bromodomain inhibitor pelabresib is positioned as pathway-agnostic — relevant for the substantial minority of CALR or MPL mutation carriers less amenable to JAK2-centric therapies. The European Bioinformatics Institute maintains curated genomic data on these MPN driver mutations.

A 2022 literature record from Tisch Cancer Institute (Mount Sinai) notes that current European LeukemiaNet cytoreductive guidelines rely heavily on hydroxyurea, pegylated interferon α-2a, and ruxolitinib after hydroxyurea failure, with only retrospective evidence supporting thrombosis reduction and no demonstrated disease modification — framing the primary unmet need for agents like hepcidin mimetics and LSD1 inhibitors. Explore PatSnap's life sciences intelligence tools for deeper MPN target analysis.

A 2022 literature record from Tisch Cancer Institute (Mount Sinai) contextualises the unmet need: current European LeukemiaNet (ELN) cytoreductive guidelines rely heavily on hydroxyurea, pegylated interferon α-2a, and ruxolitinib after hydroxyurea failure, with only retrospective evidence supporting thrombosis reduction and no demonstrated disease modification. Novel agents are described as being in development "with the ultimate goal of not only reducing thrombotic burden but also preventing disease progression."

A genomic disease-evolution case report from Germans Trias i Pujol Research Institute (2020) documented JAK2V617F-positive PV progressing to chronic myelomonocytic leukemia (CMML), confirmed by next-generation sequencing — underscoring the clinical urgency for disease-modifying agents. The Incyte Corporation matched cohort analysis (2023) compares hydroxyurea versus ruxolitinib in ET, referencing a Phase 2 study (NCT00726232), providing real-world clinical context for current standard-of-care benchmarks against which novel agents will be judged.

Protagonist Therapeutics' hepcidin mimetic filings reference preclinical animal model data (Casu et al., Blood 2016) demonstrating hematocrit normalization in JAK2-mutant PV mice following minihepcidins — a preclinical translational foundation. The breadth of jurisdictional filings (five jurisdictions, 2021–2026) is consistent with a compound in or approaching clinical development, though no IND submission or Phase-specific efficacy result for rusfertide is directly present in the retrieved records. Explore PatSnap's data trust and compliance standards for how this intelligence is sourced and validated.

The MANIFEST Phase 2 abstract (EHA 2023) constitutes the strongest direct clinical evidence in the dataset — representing Phase 2 data for a novel BET inhibitor (pelabresib) in high-risk ET. The European Medicines Agency has published guidance on MPN clinical trial design that contextualises these endpoints.